Literature DB >> 21407062

Management of chest wall reconstruction after resection for cancer: a retrospective study of 22 consecutive patients.

Romain Bosc1, Christophe Lepage, Cynthia Hamou, Nadia Matar, Marc-David Benjoar, Michael Hivelin, Laurent Lantieri.   

Abstract

AIM: In this study, we report our experience on immediate reconstruction after resection of primary or metastatic chest wall tumors, to restore protective function and elasticity of chest or sternum.
METHODS: Between 2005 and 2009, 22 patients underwent reconstruction using a free or pedicled flap combined, or not, to alloplastic materials (Goretex®) in order to cover full-thickness defects of the chest wall after cancer surgery. Reconstruction was immediate in all cases.
RESULTS: Mean follow-up was 27 months. Of these, 18 patients were alive at the end of the study (81.5%). Eighteen patients had malignant tumors (82%); within these patients, 12 were alive without recurrence at the end of the study (67%). The average size of the chest wall defect was 255 cm². Goretex® Mesh was used in 8 patients. All patients benefited from reconstruction with a flap: pedicled or free latissimus dorsi flap (n = 15), pedicled great omentum (n=3), deep inferior epigastric perforator free flap (n = 3), and parascapular pedicled flap (n=1).
CONCLUSION: In this series, we were able to achieve long-term palliation and even cure in some patients by resecting full-thickness chest wall in local primary or recurrence of breast cancer without increasing morbidity. The same process was used successfully in association with adjuvant treatment in other tumors like skin sarcoma. We have followed a surgical algorithm according to the tumor localization and etiology.

Entities:  

Mesh:

Year:  2011        PMID: 21407062     DOI: 10.1097/SAP.0b013e3181f9b292

Source DB:  PubMed          Journal:  Ann Plast Surg        ISSN: 0148-7043            Impact factor:   1.539


  8 in total

1.  Hump-like giant desmoid tumor of the chest: a postresectional reconstruction challenge.

Authors:  Ahmed G Elkhouly; Valerio Cervelli; Giuseppe Sanese; Eugenio Pompeo
Journal:  AME Case Rep       Date:  2017-11-17

2.  Non-rigid reconstruction of chest wall defects after resection of musculoskeletal tumors.

Authors:  Satoshi Tsukushi; Yoshihiro Nishida; Hideshi Sugiura; Yoshihisa Yamada; Yuzuru Kamei; Kazuhiro Toriyama; Naoki Ishiguro
Journal:  Surg Today       Date:  2014-03-06       Impact factor: 2.549

3.  [Combined split ALT/TFL flap for soft tissue coverage in large thoracical defects].

Authors:  M Pelzer; G Germann; C Czermak; M Reichenberger
Journal:  Chirurg       Date:  2014-01       Impact factor: 0.955

4.  Contributing factors to the outcome of primary malignant chest wall tumors.

Authors:  Abdel Rahman Mohamed Abdel Rahman; Mohamed Rahouma; Rabab Gaafar; Sherif Bahaa; Iman Loay; Mohamed Kamel; Hoda Abdelbaki; Maha Yahia
Journal:  J Thorac Dis       Date:  2017-12       Impact factor: 2.895

5.  Perforator Flaps Covering Alloplastic Materials in Full-Thickness Chest Wall Defects Reconstruction: A Safe Option?

Authors:  Cristina Aubá; Álvaro Cabello; Emilio García-Tutor; Antonio Vila; Shan Shan Qiu; Wenceslao Torre
Journal:  Plast Reconstr Surg Glob Open       Date:  2017-05-25

6.  Sternectomy for Treating Advanced Non-Melanoma Skin Cancer.

Authors:  Victor Emmanuel Gadelha Pinheiro; Bianca Rohsner Bezerra; Luís Arthur Brasil Gadelha Farias; Irapuan Teles de Araujo Filho; Marcio Ribeiro Studart da Fonseca
Journal:  J Skin Cancer       Date:  2019-05-30

Review 7.  Chest wall reconstruction in benign and malignant tumors with non-rigid materials: An overview.

Authors:  Sara Colella; Alessandro Brandimarte; Roberta Marra; Stefano Marinari; Armida D'Incecco; Milena Di Genesio Pagliuca; Andrea De Vico; Roberto Crisci; Duilio Divisi
Journal:  Front Surg       Date:  2022-08-03

8.  Primary malignant chest wall tumors: analysis of 40 patients.

Authors:  Reza Bagheri; Seyed Ziaollah Haghi; Mahmoud Reza Kalantari; Alireza Sharifian Attar; Maryam Salehi; Azadeh Tabari; Maliheh Soudaneh
Journal:  J Cardiothorac Surg       Date:  2014-06-19       Impact factor: 1.637

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.